Updated on 22 May 2015
The Global Health Innovative Technology Fund (GHIT Fund) of Japan, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, will undertake additional investments of nearly $11 million that bring its portfolio to approximately $43 million.
Launched in April 2013, GHIT Fund is a unique public health partnership that brings Japanese know-how and investment to the global fight against infectious diseases. GHIT Fund is a public-private partnership between six Japanese pharmaceutical companies, the Japanese Government and the Bill & Melinda Gates Foundation.
GHIT Fund is expanding its technology scope to include diagnostic tests, its disease portfolio to include leishmaniasis, and its Screening Platform to include four additional Japanese companies and their unique chemical compound libraries.
GHIT Fund will invest in the development of a new point-of-care test for the diagnosis of schistosomiasis. Concurrently, GHIT will further invest in the continued development and registration of a pediatric formulation of praziquantel, the gold standard treatment for schistosomiasis. These two investments combined make the GHIT pipeline in schistosomiasis one of the most robust in the world.
Other investments include new funding for a new visceral leishmaniasis (VL) drug and the expansion of GHIT's Screening Platform for malaria and tuberculosis to include four new Japanese entities: Daiichi Sankyo RD Novare Co., Ltd., Dainippon Sumitomo, Mitsubishi Tanabe Pharma, and Op Bio Factory Co., Ltd. of Okinawa.